LivaNova PLC (NASDAQ:LIVN)’s share price was up 1.3% during mid-day trading on Tuesday . The stock traded as high as $50.38 and last traded at $50.30, with a volume of 493,575 shares trading hands. The stock had previously closed at $49.65.

Separately, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $59.00 price objective (down previously from $61.00) on shares of LivaNova PLC in a research report on Thursday, July 7th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. LivaNova PLC presently has an average rating of “Hold” and a consensus target price of $66.25.

The stock’s 50-day moving average is $49.46 and its 200-day moving average is $52.79. The stock’s market cap is $2.46 billion.

In related news, Director Hugh M. Morrison sold 3,600 shares of LivaNova PLC stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $48.00, for a total transaction of $172,800.00. Following the completion of the sale, the director now directly owns 5,215 shares of the company’s stock, valued at approximately $250,320. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova PLC stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $50.07, for a total value of $50,070.00. Following the sale, the director now directly owns 64,137 shares of the company’s stock, valued at $3,211,339.59. The disclosure for this sale can be found here.

A number of hedge funds have recently added to or reduced their stakes in the company. California Public Employees Retirement System purchased a new stake in LivaNova PLC during the fourth quarter valued at $10,924,000. Wells Fargo & Company MN purchased a new stake in LivaNova PLC during the fourth quarter valued at $30,246,000. Rhumbline Advisers purchased a new stake in LivaNova PLC during the fourth quarter valued at $4,830,000. Morgan Stanley purchased a new stake in LivaNova PLC during the fourth quarter valued at $1,985,000. Finally, Fernwood Investment Management LLC purchased a new stake in LivaNova PLC during the fourth quarter valued at $1,032,000.

LivaNova PLC is a United Kingdom-based medical technology company. The Company focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company operates under three business units: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. The Company provides solutions for patients, healthcare professionals and healthcare systems.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.